Showing 381 - 400 results of 404 for search 'presented left ventricular function', query time: 0.14s Refine Results
  1. 381

    Surgeons are apprehensive to use DCD lungs despite similar post-transplant outcomes: A 20-year UNOS retrospective analysis by J. Sam Meyer, MSc, Oliver K. Jawitz, MD, MHS, Yury Peysakhovich, MD, Dan Aravot, MD, Matthew G. Hartwig, MD, MHS, Yaron D. Barac, MD, PhD

    Published 2025-02-01
    “…DBD lungs consistently improved [95% 1.46–2.57, p < 0.001].Rejected DCD lungs were associated with donors with higher cardiopulmonary function. Left ventricular ejection fractions in discarded DCD lung donors were higher than those of discarded DBD lung donors (DCD 56.9% ± 13.6 vs. …”
    Get full text
    Article
  2. 382

    State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age by Roy Rasalam, Andrew Sindone, Gary Deed, Ralph G. Audehm, John J. Atherton

    Published 2025-06-01
    “…Abstract Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. …”
    Get full text
    Article
  3. 383
  4. 384

    Takotsubo syndrome in a heart transplant recipient with poor cardiac sympathetic reinnervation by Ryo Miyake, Kisho Ohtani, Toru Hashimoto, Ryoko Yada, Tasuku Sato, Yoko Shojima, Shunji Hayashidani, Taiki Higo, Hiroyuki Tsutsui

    Published 2020-06-01
    “…Abstract Takotsubo syndrome (TTS), also referred to as stress cardiomyopathy, is characterized by transient left ventricular apical ballooning in the absence of obstructive coronary artery disease. …”
    Get full text
    Article
  5. 385

    Frailty determinants in heart failure: Inflammatory markers, cognitive impairment and psychosocial interaction by Marta Wleklik, Christopher S. Lee, Łukasz Lewandowski, Michał Czapla, Maria Jędrzejczyk, Heba Aldossary, Izabella Uchmanowicz

    Published 2025-06-01
    “…These interactions remained significant after adjustment for HF type and left ventricular ejection fraction (LVEF) and were consistent across stratifications by these factors. …”
    Get full text
    Article
  6. 386

    Type I primary neuropathic amyloidosis (Andrade, Portuguese): a clinical and laboratory study of 21 cases Neuropatia amilóide primária tipo I (Andrade, Portuguesa): estudo clínico... by Eduardo M. Azevedo, Milberto Scaff, Horacio M. Canelas, Antonio Spina-França

    Published 1975-06-01
    “…The electrocardiography showed repolarization disorders in 11 cases, left ventricular overload in 6 cases and atrioventricular block in 5 cases. …”
    Get full text
    Article
  7. 387

    Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs by Federica Tramontana, Azmi Mohammed, Yaasir H Mamoojee, Richard Quinton

    Published 2025-06-01
    “…Originally envisaged as purely oral hypoglycaemic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now increasingly prescribed in chronic kidney disease (CKD), ischaemic heart disease and left ventricular impairment, irrespective of glycaemia, and the likelihood of co-prescription with testosterone is thus increased considerably. …”
    Get full text
    Article
  8. 388

    KChIP2 genotype dependence of transient outward current (Ito) properties in cardiomyocytes isolated from male and female mice. by Lara Waldschmidt, Vera Junkereit, Robert Bähring

    Published 2017-01-01
    “…For this purpose we performed whole-cell patch-clamp experiments on isolated left ventricular cardiomyocytes from male and female mice which had different KChIP2 genotypes; i.e., wild-type (KChIP2+/+), heterozygous knockout (KChIP2+/-) or complete knockout of KChIP2 (KChIP2-/-). …”
    Get full text
    Article
  9. 389
  10. 390

    Nanoscale piezoelectric patches preserve electrical integrity of infarcted hearts by Luís M. Monteiro, Pedro J. Gouveia, Francisco Vasques-Nóvoa, Susana Rosa, Ifigeneia Bardi, Rita N. Gomes, Simão Correia-Santos, Leonardo Ricotti, Lorenzo Vannozzi, Daniele Guarnera, Liliana Costa, André M. Leite-Moreira, Pedro Mendes-Ferreira, Adelino F. Leite-Moreira, Filippo Perbellini, Cesare M. Terracciano, Perpétua Pinto-do-Ó, Lino Ferreira, Diana S. Nascimento

    Published 2025-06-01
    “…Epicardial implantation of Piezo patches in acutely infarcted mice hearts significantly improved myocardial electrical integrity without disturbing systolic function. Moreover, Piezo patches partially prevented ischemia-related adverse cardiac remodeling, reducing left ventricular chamber dilatation and compensatory hypertrophy. …”
    Get full text
    Article
  11. 391

    Characterization of novel arrhythmogenic patterns arising secondary to heterogeneous expression and activation of Nav1.8 by Zhong-He Zhang, Zhong-He Zhang, Zhong-He Zhang, Hector Barajas-Martinez, Hector Barajas-Martinez, Hector Barajas-Martinez, Hong-Yi Duan, Hong-Yi Duan, Hong-Yi Duan, Guo-Hua Fan, Hong Jiang, Hong Jiang, Hong Jiang, Charles Antzelevitch, Charles Antzelevitch, Hao Xia, Hao Xia, Hao Xia, Dan Hu, Dan Hu, Dan Hu

    Published 2025-03-01
    “…Notably, the expression of SCN10A is not uniform, showing variable expression in each cardiac chamber. The present study aims to explore the functional significance of Nav1.8 expression among different cell types present in the ventricular myocardium.MethodsThe effect of the specific Nav1.8 blocker, A-803467, on action potential was recorded from epicardial, mid-myocardial (M cells) and Purkinje tissue slices isolated from the canine left ventricle using standard microelectrode techniques and on late sodium current from Purkinje cells using patch-clamp techniques.ResultsA-803467 treatment did not significantly affect maximum diastolic potential, action potential amplitude or maximum rate of rise of the action potential upstroke in epicardial cells, M cells or Purkinje fibers. …”
    Get full text
    Article
  12. 392

    Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST‐Segment–Elevation Myocardial Infarction: Influence of the Definition Used by José A. Barrabés, Javier Inserte, Laura Castellote, Irene Buera, Laia Milà, Antonia Sambola, Aitor Uribarri, Maria Vidal, David Aluja, Sara Delgado‐Tomás, Pablo E. Tobías‐Castillo, Maria Calvo‐Barceló, Andrea Guala, José F. Rodríguez‐Palomares, Bruno García del Blanco, David Beneítez, Ignacio Ferreira‐González

    Published 2025-06-01
    “…Transferrin saturation <20%, but not ferritin‐based criteria, was associated with poorer clinical course and left ventricular function and higher in‐hospital mortality and remained an independent predictor of impaired reperfusion after adjusting for baseline predictors and anemia. …”
    Get full text
    Article
  13. 393

    Prevalence and Factors Associated with Excess Weight in Patients with Heart Failure in Cali, Colombia by Jhonatan Betancourt-Peña, Julieth Paola Suárez-Hernández, Guillermo Perlaza-Peláez, William Eduardo Escobar-Rodríguez, Adriana Orejuela-Upegui, Mauricio Hernández-Carrillo

    Published 2025-08-01
    “…Patients with HF aged under 65 years and with reduced or moderate left ventricular ejection fraction show a lower probability of excess weight. …”
    Get full text
    Article
  14. 394

    Characteristics of patients with chronic heart failure in different age groups by R. I. Jafarov, G. E. Bayramova, M. M. Bagirov, Kh. A. Alieva, Z. K. Rakhmanov, A.  B. Hajiev

    Published 2023-05-01
    “…In view of the above, the aim of the present study was to compare NT-proBNP level, other basic parameters of left ventricular myocardial contractility and the results of 6-min walk test, in CHF patients of different age. …”
    Get full text
    Article
  15. 395

    Pharmacoepidemiological analysis of therapy for chronic heart failure by D. D. Monakhova, V. A. Shchegoleva, T. I. Spiridonova

    Published 2023-09-01
    “…Men and women, aged from 50 to 80 years, with functional class (FC) II to IV, with reduced left ventricular ejection fraction (&lt; 40 %) and with such diseases in anamnesis as arterial hypertension, coronary heart disease, atherosclerosis, diabetes mellitus were in the inclusion group. …”
    Get full text
    Article
  16. 396

    Pulmonary arterial hypertension: Navigating the pathways of progress in diagnosis, treatment, and patient care by Miguel Azaredo Raposo, Daniel Inácio Cazeiro, Tatiana Guimarães, Nuno Lousada, Céline Freitas, Joana Brito, Susana Martins, Catarina Resende, Peter Dorfmüller, Rita Luís, Susana Moreira, Pedro Alves da Silva, Luís Moita, Mário Oliveira, Fausto J. Pinto, Rui Plácido

    Published 2024-12-01
    “…Pulmonary arterial hypertension (PAH) is a form of precapillary pulmonary hypertension caused by a complex process of endothelial dysfunction and vascular remodeling. If left untreated, this progressive disease presents with symptoms of incapacitating fatigue causing marked loss of quality of life, eventually culminating in right ventricular failure and death. …”
    Get full text
    Article
  17. 397
  18. 398

    Validation of Takotsubo Syndrome Scoring System by Dana Deeb, Ranel Loutati, Louay Taha, Mohammad Karmi, Akiva Brin, Ofir Rabi, Nir Levi, Noam Fink, Pierre Sabouret, Mohammed Manassra, Abed Qadan, Motaz Amro, Benyamin Khalev, Michael Glikson, Elad Asher

    Published 2025-05-01
    “…A 10-point scoring system was used: stressful events (three points), female gender (two points), no history of diabetes mellitus (two points), estimated left ventricular ejection fraction (LVEF) ≤ 40% on admission echocardiography (one point), positive troponin on admission (one point), and no smoking (one point). …”
    Get full text
    Article
  19. 399

    Does Levosimendan hasten veno-arterial ECMO weaning? A propensity score matching analysis by Nicolas Paulo, Antoine Kimmoun, David Hajage, Pierre Hubert, David Levy, Marc Pineton de Chambrun, Juliette Chommeloux, Ouriel Saura, Grégoire Del Marmol, Quentin Moyon, Guillaume Hékimian, Melchior Gautier, Charles Edouard Luyt, Guillaume Lebreton, Bruno Levy, Alain Combes, Matthieu Schmidt

    Published 2025-04-01
    “…However, the literature is limited and presents conflicting results. We aimed to assess the benefits of levosimendan on VA-ECMO for time to successful ECMO weaning, using a pragmatic and rigorous definition of successful VA-ECMO weaning in patients with potential for cardiac function recovery. …”
    Get full text
    Article
  20. 400